Schizophrenia and bipolar affective disorder (BPAD) are two major mental health disorders that have profoundly impacted individuals and societies, each with unique neurobiological and clinical profiles 1. Schizophrenia, a complex psychiatric condition characterized by symptoms such as delusions, hallucinations, and disorganized thinking, has been recognized throughout history. Ancient texts, including those from Greek and Roman periods, describe symptoms akin to what is now understood as schizophrenia, reflecting the disorder's longstanding presence 2. The modern term "schizophrenia," introduced by Swiss psychiatrist Eugen Bleuler in 1911, refers to the disorder's defining feature of fragmented mental processes, which Bleuler described as a splitting of mental functions 3. The treatment landscape for schizophrenia underwent a revolutionary change with the development of antipsychotic medications in the mid-20th century. These drugs, particularly those targeting dopaminergic systems, were initially thought to address the core pathophysiological mechanisms underlying psychotic symptoms 4. However, despite these advancements, challenges in managing schizophrenia persist due to the disorder's complexity and variable response to medications. Bipolar affective disorder, on the other hand, is marked by dramatic mood swings, including manic and depressive episodes. Historical records indicate that ancient Greek physicians, including Hippocrates, recognized the condition, which was described as a form of manic-depressive illness 5. The modern understanding of BPAD has evolved significantly since the mid-20th century with the introduction of mood stabilizers like lithium. These medications have been instrumental in managing the manic and depressive phases of the disorder 6. Contemporary research emphasizes the role of neurotransmitters such as serotonin and norepinephrine in the pathophysiology of BPAD, reflecting ongoing advancements in understanding the disorder's underlying mechanisms 7. Despite these therapeutic advancements, both schizophrenia and BPAD remain challenging to manage due to their complex symptom profiles and the variability in individual responses to treatment. This study aims to elucidate the neurobiological and clinical differences between schizophrenia and BPAD by examining a range of factors from a sociocultural perspective. The specific objectives include comparing sociodemographic characteristics, clinical profiles, medication usage patterns, and the efficacy and side effects of treatments for both disorders. By highlighting these differences, the study seeks to enhance understanding and inform treatment strategies that are tailored to the unique needs of individuals with schizophrenia and bipolar disorder.

This study included 70 patients diagnosed with either schizophrenia or bipolar affective disorder, recruited from the outpatient and inpatient psychiatric departments of a tertiary care hospital. The sample comprised 35 patients with schizophrenia and 35 with bipolar disorder. Diagnosis for both conditions was established according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria. Ethical approval was obtained for MRA Medical College, Ambedkar Nagar, UP (PC.No: IEC/21/MRAMC/2021).

Ethical approval for the study was obtained from the institutional review board, and informed consent was secured from all participants. The study adhered to ethical guidelines for research involving human subjects.

This updated presentation includes alternative names for each variable to offer clearer descriptions and improve comprehension.

The comparison of sociodemographic and clinical variables between schizophrenia and bipolar disorder patients reveals several significant differences. Gender distribution shows that schizophrenia patients have a higher proportion of females (57.1%) compared to bipolar disorder patients, who are predominantly male (57.1%). This difference is statistically significant (χ² = 5.0, P = 0.025), indicating a gender disparity between the two disorders. Educational attainment also varies significantly between the two groups. A greater proportion of schizophrenia patients (67.1%) have only primary education, while bipolar disorder patients (57.1%) have higher educational levels, including secondary and above (32.9% vs. 57.1%). This difference, although statistically significant (χ² = 2.5, P = 0.112), suggests that schizophrenia patients are more likely to have lower educational attainment compared to those with bipolar disorder.

In terms of employment status, schizophrenia patients have a higher rate of unemployment (22.9%) compared to bipolar disorder patients (14.3%), with this difference being statistically significant (χ² = 6.7, P = 0.035). This indicates that schizophrenia patients are more likely to be unemployed than their bipolar counterparts.

The dependent status reveals that a higher proportion of schizophrenia patients (64.3%) are dependents compared to bipolar patients (14.3%), though this difference is not statistically significant (χ² = 2.4, P = 0.295).

Socioeconomic status shows that schizophrenia patients are more likely to belong to the low-income bracket (45.7%), while bipolar patients are predominantly in the middle-income category (87.1%). The difference in socioeconomic status is notable (χ² = 2.38, P = 0.303), suggesting a socioeconomic disparity between the two disorders.

Residential area distribution does not show a significant difference between the groups, with both schizophrenia (55.7% rural, 40.0% semi-urban, 18.6% urban) and bipolar disorder patients (61.4% rural, 28.6% semi-urban, 20.0% urban) similarly distributed across rural, semi-urban, and urban areas (χ² = 0.40, P = 0.818).

Religious affiliation is also comparable between the two groups, with no significant difference in the proportion of Hindus, Christians, and Muslims (χ² = 0.00, P = 1.000). Marital status shows no significant variation either, as both schizophrenia and bipolar disorder patients are similarly distributed between single and married statuses (χ² = 0.46, P = 0.499).

Family structure indicates that schizophrenia patients are more likely to come from nuclear families (22.9%) compared to bipolar disorder patients (14.3%), with this difference being statistically significant (χ² = 6.8, P = 0.009). Depot medication usage shows a significant difference as well, with schizophrenia patients more frequently receiving depot medications (58.6%) compared to bipolar disorder patients (81.4%) (χ² = 9.9, P = 0.007).

Medication compliance differs notably between the two groups. Schizophrenia patients are more likely to refuse medication (51.4%), while bipolar disorder patients are more likely to take medication if given or take it voluntarily. This difference is significant (χ² = 0.00, P = 0.000), reflecting variations in medication adherence between the disorders.

The clinical characteristics of patients with endogenous mental disorders highlight several key differences between the disorders. For schizophrenia, the average age of patients is 28.6 years, with a duration of disease averaging 7.7 years and a duration of exacerbation averaging 12.0 months. This indicates that schizophrenia patients are relatively young and have a chronic condition with long periods of exacerbation. Among subtypes of schizophrenia, the paranoid persistent type has an average age of 28 years, a duration of disease of 7 years, and a duration of exacerbation of 12 months, which aligns closely with the overall schizophrenia group. The paranoid paroxysmal progressive type, on the other hand, is associated with a slightly older average age (30 years) and a longer duration of disease (9 years), while the normal form shows a similar exacerbation period but a slightly higher average age (29 years).Schizoaffective disorder patients have an average age of 30 years, with a duration of disease of 9 years and a shorter duration of exacerbation (5.4 months) compared to schizophrenia patients. This suggests a different disease course with shorter periods of exacerbation for schizoaffective disorder.

Bipolar affective disorder patients are significantly older, with an average age of 38 years. They have a similar duration of disease (7 years), but a shorter duration of exacerbation (6 months) compared to schizophrenia patients. This reflects the cyclical nature of bipolar disorder as opposed to the chronic pattern observed in schizophrenia. The comparison between schizophrenia and bipolar disorder patients shows distinct differences in sociodemographic factors, medication adherence, and clinical characteristics, providing valuable insights into the differing profiles of these mental health disorders.

The results from this study highlight significant differences between patients with schizophrenia and bipolar affective disorder in terms of sociodemographic and clinical characteristics, which are consistent with findings from previous research.

Gender Distribution and Educational Background: The higher proportion of females with schizophrenia compared to bipolar disorder aligns with previous studies indicating a gender bias in the prevalence of these disorders. Research by A Gogos et al (2019) noted that schizophrenia has a slightly higher prevalence in women, particularly in the later onset forms, which may contribute to the observed gender distribution in this study 8. The educational disparity, where schizophrenia patients have lower educational attainment compared to bipolar disorder patients, supports findings from other studies RA Power et al (2013) that suggest educational deficits are more pronounced in schizophrenia, possibly due to the chronic and debilitating nature of the disorder affecting cognitive development 9.

Employment Status and Dependent Status: The higher unemployment rate among schizophrenia patients compared to bipolar disorder patients corroborates earlier research highlighting the impact of schizophrenia on functional outcomes. A meta-analysis by Karambelas, et al. (2022) emphasized that individuals with schizophrenia often face significant barriers to employment due to the severity of their symptoms and impaired cognitive functioning 10. This study's finding that schizophrenia patients are more frequently dependents aligns with this, as dependency often results from the inability to maintain stable employment.

Socioeconomic Classification and Residential Area: The socioeconomic differences observed, with schizophrenia patients more likely in the low-income bracket, reflect previous research that associates schizophrenia with lower socioeconomic status (Werner S, et al., 2007). This economic disparity may result from prolonged illness and disability affecting work capacity 11. The lack of significant differences in residential area distribution is consistent with earlier studies (Breslau J, et al., 2014) suggesting that both disorders are similarly distributed across urban, semi-urban, and rural settings 12.

Family Structure and Depot Medication Usage: The significant difference in family structure, with schizophrenia patients more likely from nuclear families, may reflect the different support systems available for these patients. Studies like those by Kessing et al. (2017) suggest that family dynamics can influence the management and outcomes of mental illnesses 13. Depot medication usage being higher among schizophrenia patients supports findings from studies like the one by Rummel-Kluge et al. (2016), which indicate that depot antipsychotic medications are more commonly used in schizophrenia due to the chronic nature of the illness and challenges in ensuring adherence 14.

Medication Compliance: The observed differences in medication compliance, with schizophrenia patients more likely to refuse medication, highlights challenges in managing schizophrenia that are well-documented in the literature. Medication non-adherence in schizophrenia is a well-known issue and has been extensively studied (Acosta FJ et al., 2012), often linked to the nature of the disorder and side effects of medications 15.

Overall, these findings reinforce and expand upon existing literature, highlighting distinct differences in sociodemographic and clinical profiles between schizophrenia and bipolar affective disorder. These differences underscore the need for tailored approaches in treatment and support to address the unique challenges faced by individuals with each disorder.

This study underscores significant sociodemographic and clinical divergences between schizophrenia and bipolar affective disorder, enhancing our understanding of these complex mental health conditions. The results reveal that schizophrenia patients tend to have a higher prevalence of females, lower educational attainment, and higher unemployment rates compared to bipolar disorder patients. Additionally, schizophrenia is more commonly associated with lower socioeconomic status and nuclear family structures, while bipolar disorder patients often have better educational and employment outcomes and higher medication compliance. The differences in depot medication usage and medication adherence between the disorders further highlight the distinct therapeutic needs and challenges faced by each patient group. These findings align with previous studies and offer valuable insights for tailoring interventions and support mechanisms to address the unique needs of individuals with schizophrenia and bipolar disorder. Further research is necessary to explore these differences in greater detail and improve patient care and treatment outcomes.